Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SLE
MCID: LPS004
MIFTS: 61

Lupus Erythematosus (SLE)

Categories: Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Lupus Erythematosus

About this section

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 74 20 54 15 71 32
Lupus 12 20 42 3 15
Subacute Cutaneous Lupus 20 71
Disseminated Lupus Erythematosus 20
Lupus Erythematosus, Systemic 71
Systemic Lupus Erythematosus 20
Lupus Erythematosus, Discoid 71
Lupus Vulgaris 71
Discoid Lupus 20
Sle 20

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Skin diseases Immune diseases Nephrological diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8857
ICD9CM 34 695.4
NCIt 50 C27153
SNOMED-CT 67 200936003
ICD10 32 L93
UMLS 71 C0024131 C0024138 C0024141 more
Sources

Summaries for Lupus Erythematosus

About this section
MedlinePlus : 42 What is lupus? Lupus is an autoimmune disease. This means that your immune system attacks healthy cells and tissues by mistake. This can damage many parts of the body, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain. There are several kinds of lupus Systemic lupus erythematosus (SLE) is the most common type. It can be mild or severe and can affect many parts of the body. Discoid lupus causes a red rash that doesn't go away Subacute cutaneous lupus causes sores after being out in the sun Drug-induced lupus is caused by certain medicines. It usually goes away when you stop taking the medicine. Neonatal lupus, which is rare, affects newborns. It is probably caused by certain antibodies from the mother. What causes lupus? The cause of lupus is unknown. Who is at risk for lupus? Anyone can get lupus, but women are most at risk. Lupus is two to three times more common in African American women than in white women. It's also more common in Hispanic, Asian, and Native American women. African American and Hispanic women are more likely to have severe forms of lupus. What are the symptoms of lupus? Lupus can have many symptoms, and they differ from person to person. Some of the more common ones are Pain or swelling in joints Muscle pain Fever with no known cause Red rashes, most often on the face (also called the "butterfly rash") Chest pain when taking a deep breath Hair loss Pale or purple fingers or toes Sensitivity to the sun Swelling in legs or around eyes Mouth ulcers Swollen glands Feeling very tired Symptoms may come and go. When you are having symptoms, it is called a flare. Flares can range from mild to severe. New symptoms may appear at any time. How is lupus diagnosed? There is no specific test for lupus, and it's often mistaken for other diseases. So it may take months or years for a doctor to diagnose it. Your doctor may use many tools to make a diagnosis: Medical history Complete exam Blood tests Skin biopsy (looking at skin samples under a microscope) Kidney biopsy (looking at tissue from your kidney under a microscope) What are the treatments for lupus? There is no cure for lupus, but medicines and lifestyle changes can help control it. People with lupus often need to see different doctors. You will have a primary care doctor and a rheumatologist (a doctor who specializes in the diseases of joints and muscles). Which other specialists you see depends on how lupus affects your body. For example, if lupus damages your heart or blood vessels, you would see a cardiologist. Your primary care doctor should coordinate care between your different health care providers and treat other problems as they come up. Your doctor will develop a treatment plan to fit your needs. You and your doctor should review the plan often to be sure it is working. You should report new symptoms to your doctor right away so that your treatment plan can be changed if needed. The goals of the treatment plan are to Prevent flares Treat flares when they occur Reduce organ damage and other problems Treatments may include drugs to Reduce swelling and pain Prevent or reduce flares Help the immune system Reduce or prevent damage to joints Balance the hormones Besides taking medicines for lupus, you may need to take medicines for problems that are related to lupus such as high cholesterol, high blood pressure, or infection. Alternative treatments are those that are not part of standard treatment. At this time, no research shows that alternative medicine can treat lupus. Some alternative or complementary approaches may help you cope or reduce some of the stress associated with living with a chronic illness. You should talk to your doctor before trying any alternative treatments. How can I cope with lupus? It is important to take an active role in your treatment. It helps to learn more about lupus - being able to spot the warning signs of a flare can help you prevent the flare or make the symptoms less severe. It is also important to find ways to cope with the stress of having lupus. Exercising and finding ways to relax may make it easier for you to cope. A good support system can also help. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to cutaneous lupus erythematosus and systemic lupus erythematosus 16, and has symptoms including rashes, seizures and pruritus. An important gene associated with Lupus Erythematosus is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Pioglitazone and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and kidney, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An autoimmune disease that is characterized by a constellation of findings that include elevated antibodies to nuclear antigens, antiphospholipids, low complement levels, ulcers, non-scarring alopecia, renal or neurologic damage, and low white blood cell and platelet counts, has symptom rashes, fatigue, arthritis, hair loss, seizures, and symptoms related to affected organs.

GARD : 20 Lupus is an autoimmune disease that can affect almost every organ in the body. Symptoms of lupus can range from very mild to life-threatening. There are three main types of lupus; systemic lupus erythematosus, discoid lupus, and drug-induced lupus. Symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. Genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors. Studies suggest that a number of different genes may be involved in determining a person's likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. Lupus is more common in young women. The treatment of lupus depends on the severity of the condition and what parts of the body are affected. Treatment may include acetaminophen, ibuprofen, antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as BLyS-specific inhibitors (Belimumab).

CDC : 3 Lupus is an autoimmune disease that causes inflammation in different parts of the body. An autoimmune disease occurs when the body's immune system attacks itself. Its symptoms can show up in many different ways, which sometimes makes it hard to diagnose. Lupus symptoms can range from mild to life threatening, so early diagnosis and treatment by a rheumatologist are important. A rheumatologist is a doctor who has additional training and experience in the diagnosis and treatment of arthritis, lupus, and other diseases of the joints, muscles, and bones.

Wikipedia : 74 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Sources

Related Diseases for Lupus Erythematosus

About this section

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2382)
# Related Disease Score Top Affiliating Genes
1 cutaneous lupus erythematosus 33.7 TRIM21 IRF5 CTLA4 C1QA
2 systemic lupus erythematosus 16 33.4 DNASE1L3 DNASE1 C4A C1QA
3 subacute cutaneous lupus erythematosus 33.4 TRIM21 IRF5 C1QA
4 systemic lupus erythematosus 33.4 TRIM21 TLR5 STAT4 SSB SNRPB PTPN22
5 neonatal lupus erythematosus 33.3 TRIM21 C4A
6 vitiligo-associated multiple autoimmune disease susceptibility 1 33.1 PTPN22 PDCD1 CTLA4 C4B
7 pediatric systemic lupus erythematosus 32.9 STAT4 PTPN22 C4B C4A
8 c1q deficiency 32.9 C1QC C1QB C1QA
9 autoimmune disease 32.6 TRIM21 STAT4 PTPN22 PDCD1 ITGAM IRF5
10 exanthem 32.6 TRIM21 PDCD1 CTLA4
11 glomerulonephritis 32.4 C4B C4A C1QC C1QB C1QA
12 complement factor i deficiency 32.3 C4B C4A
13 rheumatoid arthritis 32.3 STAT4 PTPN22 PDCD1 IRF5 FCGR2B CTLA4
14 thrombocytopenia 32.3 TRIM21 TLR5 PTPN22 PDCD1 ITGAM FCGR2B
15 raynaud disease 32.0 TRIM21 SSB
16 heart block, congenital 31.7 TRIM21 SSB
17 primary biliary cholangitis 31.6 STAT4 PTPN22 PDCD1 IRF5 CTLA4
18 crohn's disease 31.6 TLR5 STAT4 PTPN22 CTLA4
19 immune deficiency disease 31.5 STAT4 ITGAM DNASE1 CR2 C4A
20 anca-associated vasculitis 31.5 PTPN22 CTLA4
21 hemophagocytic lymphohistiocytosis 31.4 IRF5 CTLA4 CR2
22 type 1 diabetes mellitus 31.4 PTPN22 PDCD1 CTLA4 C4A
23 inflammatory bowel disease 31.3 TLR5 STAT4 PTPN22 ITGAM IRF5 CTLA4
24 hypersensitivity reaction type iii disease 31.2 FCGR2B C4B C4A
25 mononeuritis multiplex 31.2 TRIM21 SSB
26 common variable immunodeficiency 31.2 ITGAM FCGR2B CTLA4 CR2
27 diffuse scleroderma 31.0 TRIM21 BANK1
28 parotitis 30.9 TRIM21 SSB
29 granulomatous hepatitis 30.8 CTLA4 CR2
30 second-degree atrioventricular block 30.8 TRIM21 SSB
31 xerophthalmia 30.7 TRIM21 SSB
32 limited scleroderma 30.7 TRIM21 SSB IRF5 BANK1
33 behcet syndrome 30.6 STAT4 PTPN22 CTLA4 C4A
34 type 1 diabetes mellitus 12 30.6 PTPN22 CTLA4
35 hemorrhagic disease 30.6 TRIM21 SSB C4B C4A
36 felty syndrome 30.6 C4B C4A
37 polyclonal hypergammaglobulinemia 30.6 TRIM21 SSB
38 multifocal motor neuropathy 30.4 PTPN22 FCGR2B BANK1
39 complement component 5 deficiency 30.4 C4B C4A C1QA
40 complement component 3 deficiency 30.4 C4B C4A
41 bone inflammation disease 30.3 PTPN22 ITGAM CTLA4
42 parotid disease 30.3 TRIM21 SSB
43 third-degree atrioventricular block 30.2 TRIM21 SSB
44 oligoarticular juvenile idiopathic arthritis 29.8 STAT4 PTPN22
45 discoid lupus erythematosus 11.8
46 lupus erythematosus tumidus 11.8
47 drug-induced lupus erythematosus 11.7
48 systemic lupus erythematosus 1 11.7
49 chilblain lupus 1 11.7
50 systemic lupus erythematosus 2 11.7

Graphical network of the top 20 diseases related to Lupus Erythematosus:



Diseases related to Lupus Erythematosus
Sources

Symptoms & Phenotypes for Lupus Erythematosus

About this section

Symptoms:

12
  • • rashes

UMLS symptoms related to Lupus Erythematosus:


seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

GenomeRNAi Phenotypes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.62 C1QA TRIM21
2 Decreased viability GR00249-S 9.62 FCGR2B IRF5 ITGAM PDCD1 SNRPB
3 Decreased viability GR00381-A-1 9.62 C1QA PDCD1 SNRPB
4 Decreased viability GR00381-A-2 9.62 C1QA
5 Decreased viability GR00381-A-3 9.62 C1QA PDCD1
6 Decreased viability GR00386-A-1 9.62 FCGR2B SNRPB
7 Decreased viability GR00402-S-2 9.62 C1QA C1QB C4B PDCD1 SNRPB

MGI Mouse Phenotypes related to Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 BANK1 C4B CR2 CTLA4 DNASE1 FCGR2B
2 homeostasis/metabolism MP:0005376 10.03 C1QA C1QB C1QC C4B CR2 CTLA4
3 immune system MP:0005387 9.83 BANK1 C1QA C4B CR2 CTLA4 DNASE1
4 renal/urinary system MP:0005367 9.28 C1QA C4B CR2 DNASE1 FCGR2B PDCD1
Sources

Drugs & Therapeutics for Lupus Erythematosus

About this section

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Lenalidomide Approved Phase 4 191732-72-6 216326
9
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
10
Lifitegrast Approved Phase 4 1025967-78-5
11
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
12
Sulfamethoxazole Approved Phase 4 723-46-6 5329
13
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
14
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
15
Metformin Approved Phase 4 657-24-9 14219 4091
16
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
17
Mycophenolic acid Approved Phase 4 24280-93-1 446541
18
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
21
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
22 Vaccines Phase 4
23 Cyclooxygenase Inhibitors Phase 4
24 Methylprednisolone Acetate Phase 4
25 Rosuvastatin Calcium Phase 4 147098-20-2
26 Antilymphocyte Serum Phase 4
27 Anti-Asthmatic Agents Phase 4
28 Phosphodiesterase 3 Inhibitors Phase 4
29 Bronchodilator Agents Phase 4
30 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
31 Thymoglobulin Phase 4
32 Omega 3 Fatty Acid Phase 4
33 Estrogens, Conjugated (USP) Phase 4
34 Hydroxycholecalciferols Phase 4
35 Ibandronic Acid Phase 4
36 Lubricant Eye Drops Phase 4
37 Antiviral Agents Phase 4
38 Angiogenesis Inhibitors Phase 4
39 Complement System Proteins Phase 4
40 Calcineurin Inhibitors Phase 4
41 Anthelmintics Phase 4
42 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
43 Complement C3 Phase 4
44 Immunosuppressive Agents Phase 4
45 Immunologic Factors Phase 4
46 Hypoglycemic Agents Phase 4
47 Cholinergic Agents Phase 4
48 Dimethoate Phase 4
49 Cholinesterase Inhibitors Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 821)
# Name Status NCT ID Phase Drugs
1 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
2 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
6 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
7 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
8 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
9 A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus Completed NCT02741960 Phase 4 metformin;placebo
10 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
11 To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
12 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed NCT00048776 Phase 4 Pletal
13 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
14 A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus Completed NCT03098823 Phase 4 RAYOS;Prednisone
15 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
16 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
17 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Completed NCT02953821 Phase 4 Acthar Gel;Placebo Gel
18 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Completed NCT01753401 Phase 4 Acthar;Placebo;Steroid Drug
19 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
20 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
21 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
22 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTAâ„¢ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
23 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
24 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
25 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
26 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
27 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
28 Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease Completed NCT03287635 Phase 4 Corticotropin 80Unit/Ml Repository Injection
29 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
30 Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
31 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
32 Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
33 Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis Completed NCT04146220 Phase 4 Prednisolone
34 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
35 Pilot Trial of Belimumab in Early Lupus Recruiting NCT03543839 Phase 4
36 Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
37 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
38 A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus Recruiting NCT04127747 Phase 4 Standard dose of rituximab;Individualized dose of rituximab
39 A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
40 Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis. Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
41 A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis: Pilot Study Recruiting NCT03214731 Phase 4 Artesunate
42 A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab Active, not recruiting NCT01705977 Phase 4
43 Sequential Belimumab Followed by T-cell Based Therapy in the Treatment of Systemic Lupus Erythematosus (SUBTLE) - a Preliminary Proof-of-concept Mechanistic Study Not yet recruiting NCT04447053 Phase 4 Belimumab Injection [Benlysta]
44 Efficacy and Safety of Belimumab for Prevention of Disease Flares in SLE Patients With Low Disease Activity Not yet recruiting NCT04515719 Phase 4
45 Metformin In Prevention Of Lupus Nephritis In High Risk Patients Not yet recruiting NCT04145687 Phase 4 Metformin
46 Comparison Between Mycophenolate andCyclophosphamide in the Treatment of Lupus Nephritis Not yet recruiting NCT04424602 Phase 4 cyclo phosphamide;mycophenolate
47 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
48 Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children Terminated NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
49 A Multicenter, Non-comparative, Open-labeled, Prospective Study to Evaluate the Efficacy and Safety of Tacrolimus (Prograf®) With Steroid in Korean Lupus Nephritis Patients Who Are Non-responders to Steroid Monotherapy Terminated NCT01316133 Phase 4 tacrolimus
50 A Randomized Open-label Study of Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis Terminated NCT03920059 Phase 4 Mycophenolate Mofetil

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Azathioprine
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
Cyclosporine
Hydroxychloroquine
Hydroxychloroquine Sulfate
prasterone
Thalidomide
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide
Sources

Genetic Tests for Lupus Erythematosus

About this section
Sources

Anatomical Context for Lupus Erythematosus

About this section

MalaCards organs/tissues related to Lupus Erythematosus:

40
T Cells, Skin, Kidney, Endothelial, B Cells, Neutrophil, Bone Marrow
Sources

Publications for Lupus Erythematosus

About this section

Articles related to Lupus Erythematosus:

(show top 50) (show all 39480)
# Title Authors PMID Year
1
Advances in ANCA-associated vasculitis and lupus nephritis. 42 61
33311560 2021
2
SARS-CoV-2 and Systemic Lupus Erythematosus. 42 61
33511495 2021
3
Clinical characteristics of systemic lupus erythematosus with chylothorax and/or chylous ascites: An analysis of 15 cases in China. 42 61
33371102 2020
4
Vaccination, atherosclerosis and systemic lupus erythematosus. 54 61
19880570 2009
5
[Association of interleukin-18 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population]. 54 61
18683145 2008
6
[The occurrence of anticardiolipin antibodies bound in circulating immunological complexes in sera of patients suffering from juvenile lupus erythematosus and juvenile idiopathic arthritis]. 61 54
19562964 2008
7
Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon. 61 54
17550096 2006
8
Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients. 61 54
16987709 2006
9
Vasculopathy and renal injury in lupus erythematosus: does shedding of the endothelial protein C receptor play a role? 61 54
15954934 2005
10
Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review. 54 61
15825571 2005
11
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients. 61 54
12716380 2003
12
Catalytic heterogenity of polyclonal RNA-hydrolyzing IgM from sera of patients with lupus erythematosus. 54 61
11208354 2000
13
Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. 61 54
10599336 1999
14
Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. 54 61
7774062 1995
15
Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. 54 61
8311089 1994
16
Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. 54 61
7686561 1993
17
Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. 61
33307926 2021
18
A novel canis lupus familiaris reference genome improves variant resolution for use in breed-specific GWAS. 61
33514656 2021
19
Lupus low disease activity (SLE) in patients treated with belimumab: a single-center real-life experience (2016-2019). 61
32797364 2021
20
Abnormal thymic B cell activation and impaired T cell differentiation in pristane-induced lupus mice. 61
33428991 2021
21
Corrigendum to 'Dental pathology of the wild Iberian wolf (Canis lupus signatus): the study of a 20th century Portuguese museum collection': Veterinary and animal science 9 (2020) 100100. 61
33490714 2021
22
Update on the cellular pathogenesis of lupus. 61
33394603 2021
23
The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. 61
33394753 2021
24
Development of chronic cutaneous lupus erythematosus during biologic therapy: A systematic review. 61
33022308 2021
25
De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. 61
32939795 2021
26
B-cell depletion or belimumab or voclosporin for lupus nephritis? 61
33186226 2021
27
Trichoscopic findings of discoid lupus erythematosus alopecia: A cross-sectional study. 61
32502590 2021
28
Lupus erythematosus eosinophil cells in a pleural effusion. 61
33400388 2021
29
New lupus criteria: a critical view. 61
33332888 2021
30
Calcified constrictive pericarditis resulting in tamponade in a patient with systemic lupus erythematosus. 61
33206224 2021
31
Successful Treatment With Multitarget Therapy of Mycophenolate Mofetil and Tacrolimus for Cyclophosphamide-Resistant Antineutrophil Cytoplasmic Antibody-Associated Pauci-Immune Glomerulonephritis Developed Independently of Systemic Lupus Erythematosus. 61
31895115 2021
32
Development of Sweet's syndrome and the immunological finding of systemic lupus erythematosus during the course of mixed connective tissue disease. 61
33040354 2021
33
Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody-Positive Patient. 61
33468561 2021
34
New therapeutic approaches in systemic lupus erythematosus. 61
33332887 2021
35
Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities. 61
33388903 2021
36
NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice. 61
33227426 2021
37
Central Nervous System Systemic Lupus Erythematosus (CNS-SLE) Vasculitis Mimicking Lewy Body Dementia: A Case Report Emphasizing the Role of Imaging With an Analysis of 33 Comparable Cases From the Scientific Literature. 61
31996085 2021
38
Orofacial manifestations and dental management of systemic lupus erythematosus: A review. 61
31886584 2021
39
Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients. 61
32603516 2021
40
Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus. 61
32797360 2021
41
Cucurbitacin IIb improved active chromatin-induced systemic lupus erythematosus via balancing the percentage of Th17 and Treg cells. 61
33128285 2021
42
Perinuclear anti-neutrophil cytoplasmic antibody in systemic lupus erythematosus indicates more severe condition. 61
33307059 2021
43
Decreased sleep quality in patients with systemic lupus erythematosus: a meta-analysis. 61
32748069 2021
44
TNFSF4 is a risk factor to systemic lupus erythematosus in a Latin American population. 61
32809147 2021
45
In-hospital mortality reduction in systemic lupus erythematosus over 2 decades varied by patient sex and age. 61
33394201 2021
46
Kikuchi-Fujimoto Disease Triggered by Systemic Lupus Erythematosus and Mycoplasma pneumoniae Infection-A Report of a Case and a Review of the Literature. 61
32809980 2021
47
Case Series: Lingual Infarction and Autoamputation in Systemic Lupus Erythematosus. 61
32332271 2021
48
COVID-19 Coagulopathy in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Antibodies. 61
32947435 2021
49
Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. 61
33589110 2021
50
Clinical features and expression of type I interferon-inducible genes in systemic lupus erythematosus patients harboring rs1143679 polymorphism in China: a single-center, retrospective study. 61
32785810 2021
Sources

Variations for Lupus Erythematosus

About this section
Sources

Expression for Lupus Erythematosus

About this section
Search GEO for disease gene expression data for Lupus Erythematosus.
Sources

Pathways for Lupus Erythematosus

About this section

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.84 TRIM21 TLR5 PTPN22 PDCD1 ITGAM IRF5
2
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 65
Show member pathways
 13.6 TRIM21 SSB SNRPB ITGAM C4B C4A
3
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.84 TLR5 STAT4 IRF5 C1QC C1QB C1QA
4
NF-kappaB Signaling 4
12.37 STAT4 PTPN22 PDCD1 IRF5 CTLA4
5
Creation of C4 and C2 activators 65
Show member pathways
 11.96 C4B C4A C1QC C1QB C1QA
6
Immune response Lectin induced complement pathway 23
Show member pathways
 11.9 ITGAM CR2 C4B C4A C1QC C1QB
7
Complement Pathway 63
Show member pathways
 11.67 C4B C4A C1QC C1QB C1QA
8
Complement and coagulation cascades 36 1
11.66 ITGAM CR2 C4B C4A C1QC C1QB
9
Pertussis 36
11.61 ITGAM C4B C4A C1QC C1QB C1QA
10
IgA-Producing B Cells in the Intestine 64
11.54 TLR5 PDCD1 FCGR2B CTLA4 CR2
11
Staphylococcus aureus infection 36
11.15 ITGAM FCGR2B C4B C4A C1QC C1QB
Sources

GO Terms for Lupus Erythematosus

About this section

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen trimer GO:0005581 9.33 C1QC C1QB C1QA
2 blood microparticle GO:0072562 9.26 C4B C4A C1QC C1QB
3 complement component C1 complex GO:0005602 8.62 C1QB C1QA

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.98 TLR5 FCGR2B CTLA4 CR2 C1QC
2 inflammatory response GO:0006954 9.95 TLR5 IRF5 FCGR2B C4B C4A
3 complement activation, classical pathway GO:0006958 9.73 CR2 C4B C4A C1QC C1QB C1QA
4 complement activation GO:0006956 9.72 C4B C4A C1QC C1QB C1QA
5 positive regulation of neuron death GO:1901216 9.69 ITGAM FCGR2B C1QA
6 innate immune response GO:0045087 9.65 TRIM21 TLR5 ITGAM IRF5 CR2 C4B
7 regulation of complement activation GO:0030449 9.63 CR2 C4B C4A C1QC C1QB C1QA
8 regulation of innate immune response GO:0045088 9.61 PTPN22 FCGR2B
9 negative regulation of B cell proliferation GO:0030889 9.6 FCGR2B CTLA4
10 histone mRNA metabolic process GO:0008334 9.59 SSB SNRPB
11 DNA catabolic process, endonucleolytic GO:0000737 9.58 DNASE1L3 DNASE1
12 negative regulation of immune response GO:0050777 9.58 PDCD1 FCGR2B CTLA4
13 negative regulation of B cell activation GO:0050869 9.57 FCGR2B BANK1
14 DNA catabolic process GO:0006308 9.56 DNASE1L3 DNASE1
15 positive regulation of apoptotic cell clearance GO:2000427 9.54 C4B C4A
16 synapse pruning GO:0098883 9.54 C1QC C1QB C1QA
17 neutrophil activation involved in immune response GO:0002283 9.52 DNASE1L3 DNASE1
18 complement-mediated synapse pruning GO:0150062 9.49 ITGAM C1QA
19 regulation of acute inflammatory response GO:0002673 9.48 DNASE1L3 DNASE1
20 vertebrate eye-specific patterning GO:0150064 9.46 ITGAM C1QA
21 regulation of neutrophil mediated cytotoxicity GO:0070948 9.43 DNASE1L3 DNASE1
22 immune system process GO:0002376 9.36 TLR5 PTPN22 PDCD1 ITGAM IRF5 CTLA4

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 TRIM21 TLR5 STAT4 SSB SNRPB PTPN22
2 amyloid-beta binding GO:0001540 9.5 ITGAM FCGR2B C1QA
3 deoxyribonuclease activity GO:0004536 9.16 DNASE1L3 DNASE1
4 complement binding GO:0001848 8.96 CR2 C4B
5 deoxyribonuclease I activity GO:0004530 8.62 DNASE1L3 DNASE1
Sources

Sources for Lupus Erythematosus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....